The relationship between different doses of dexamethasone administration (4, 5 and 6 mg) on neonatal cord blood cortisol levels to the incidence of respiratory distress syndrome in preterm neonates

Start Date01 Mar 2025

Sponsor / Collaborator

Faculty of Medicine Siriraj Hospital

TCTR20241008002

/ Not yet recruitingPhase 1/2IIT

Efficacy of Capsaicin Nasal Spray in Non-allergic rhinitis : A pilot study

Start Date01 Jan 2025

Sponsor / Collaborator

Faculty of Medicine Siriraj Hospital

TCTR20241104004

/ Not yet recruitingNot ApplicableIIT

Prevalence of HPV DNA detection among pregnant women: Promoting of self- Sampling HPV DNA testing for cervical cancer screening in pregnant women

Start Date01 Jan 2025

Sponsor / Collaborator

Faculty of Medicine Siriraj Hospital

100 Clinical Results associated with Faculty of Medicine Siriraj Hospital

0 Patents (Medical) associated with Faculty of Medicine Siriraj Hospital

191

Literatures (Medical) associated with Faculty of Medicine Siriraj Hospital

01 Jan 2025·JCO Global Oncology

Efficacy and Safety of Short Intravenous Hydration for Preventing Nephrotoxicity From High-Dose Cisplatin: A Randomized, Open-Label, Phase II Trial

Article

Author: Phisalprapa, Pochamana ; Ithimakin, Suthinee ; Thamlikitkul, Lucksamon ; Kositamongkol, Chayanis ; Srithongkul, Thatsaphan ; Jantarat, Apichart ; Setakornnukul, Jiraporn ; Thephamongkhol, Kullathorn

PURPOSEThe use of short hydration (SH) to prevent cisplatin-induced nephrotoxicity lacks substantive prospective evaluation. The aim of this study was to evaluate the safety and efficacy of SH, including those with head and neck cancer (HNC) who are at higher risks of mucositis that causes diminished oral intake.METHODS This phase II randomized noncomparative trial included patients with cancer who were scheduled to receive high-dose cisplatin (≥60 mg/m 2 ) in combination with another chemotherapy or concurrently with radiotherapy. Patients were randomly assigned to receive either the SH or conventional hydration (CH) protocol. The primary end point was the proportion of patients with increased serum creatinine (SCr) after undergoing SH. Secondary end points included the severity of SCr elevation, adverse events, cisplatin modification as a result of nephrotoxicity, duration of hospital stay, quality of life (QoL), and cost. RESULTSAmong 100 enrolled patients, 64 and 36 patients underwent the SH and CH protocols, respectively. The median duration of chemotherapy infusion and intravenous hydration were 5.79 and 27.58 hours with SH and CH, respectively. A total of 32.8% and 33.3% of the SH and CH groups, respectively, experienced SCr elevation. Grade 2 SCr elevations were rarely observed in both groups (1.6% in SH, 2.8% in CH). Rate of cisplatin modification was similar between the two groups. Out of 82 patients with HNC, the rate of SCr elevation was comparable for both hydration protocols. The QoL scores were meaningfully higher in the SH group during the second cycle of cisplatin, although the overall direct medical costs were similar.CONCLUSIONThe SH protocol is feasible and safe, with a remarkably reduced duration of administration. Thus, SH can be an alternative to CH in the prevention of cisplatin-related nephrotoxicity.

25 Nov 2024·Future Oncology

TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer

Article

Author: Danchaivijitr, Pongwut ; Lu, Shun ; Han, Ji-Youn ; Li, Ziming ; Girard, Nicolas ; Sugawara, Shunichi ; Franke, Fábio ; Okamoto, Isamu ; Rajagopalan, Rachana ; Chen, Aiying ; Ren, Natalie ; Lisberg, Aaron E ; Sun, Jong-Mu ; Pan, Edward ; Kuyama, Shoichi

For patients with advanced/metastatic non-small-cell lung cancer (NSCLC) without actionable genomic alterations and low (<50%) PD-L1 expression, pembrolizumab plus pemetrexed and platinum chemotherapy is a preferred first-line treatment. These patients have comparatively worse outcomes than those with higher PD-L1 expression, underscoring the need for new combination strategies. Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, has demonstrated encouraging antitumor activity and safety in this patient population. We describe the rationale and design of TROPION-Lung07, a randomized, open-label Phase III study assessing Dato-DXd in combination with pembrolizumab with/without platinum-based chemotherapy versus pembrolizumab plus pemetrexed and platinum-based chemotherapy in patients with advanced/metastatic non-squamous NSCLC without actionable genomic alterations and <50% PD-L1 expression. Primary study objectives are progression-free survival and overall survival.Clinical Trial Registration: NCT05555732 (ClinicalTrials.gov).

20 Nov 2024·Cureus

The Association Between Maternal Body Fat Percentage and the Risk of Gestational Diabetes Mellitus

Article

Author: Tunkemrat, Poramed ; Boriboonhirunsarn, Dittakarn ; Sunsaneevithayakul, Prasert

Objective In this study, we aimed to evaluate the relationship between body fat percentage (BFP) and the risk of gestational diabetes mellitus (GDM). Methods We conducted a cohort study involving 336 singleton pregnant women attending an antenatal care clinic before 14 weeks of gestation. Body composition was measured during their first antenatal visit by using a multi-frequency segmental body composition analyzer. GDM was diagnosed by a 50-g glucose challenge test (GCT) and a 100-g oral glucose tolerance test (OGTT) during the first visit and repeated during 24-28 weeks of gestation. Rates of GDM were compared between women with BFP ≥30% and those with BFP <30%. The ability of BFP and body mass index (BMI) to diagnose GDM was assessed, as well as their correlation. Results Of the 296 women included in the analysis, 171 had BFP ≥30%, and 125 had BFP <30%. The prevalence of GDM was 17.9%. BFP correlated well with BMI (correlation coefficient: 0.956, p<0.001). BFP ≥30% and BMI ≥25 kg/m² significantly increased the risk of GDM (22.2% vs. 12%, p=0.023 and 26.4% vs. 14.4%, p=0.014, respectively). The sensitivity of BFP ≥30% and BMI ≥25 kg/m² for GDM diagnosis was 71.1% and 43.3%, respectively while the specificity was 45.3% and 73.7%, respectively. Both BFP and BMI had comparable efficacy in diagnosing GDM [areas under the receiver operating characteristic (ROC) curves (AUC) of 0.634 and 0.642, respectively]. Conclusions BFP ≥30% and BMI ≥25 kg/m² significantly increased the risk of GDM. BFP correlated well with BMI and had similar efficacy in diagnosing GDM.

News (Medical) associated with Faculty of Medicine Siriraj Hospital

07 Dec 2020

·www.healthcareitnews.com

Huawei & Siriraj Hospital sign MoU to establish 5G powered smart platform for medical services

Huawei Technologies (Thailand) Co. Ltd. and the Faculty of Medicine, Siriraj Hospital, under Mahidol University, has signed the 5G Powered Smart Hospital Enabled with Cloud and AI Memorandum of Understanding (MoU) to establish a smart platform that will enhance innovative medical services. This MoU comes in response to the Faculty of Medicine Siriraj Hospital's mission to serve better by becoming a smart center that will apply integrated digital technologies using 5G infrastructure, artificial intelligence (AI), big data and cloud edge computing, in order to offer enhanced services. WHAT’S IT ABOUT Under the five-year agreement, Huawei will provide 5G technology to the Faculty, enabling the immediate upgrade of the existing infrastructure. It will also share knowledge and collaborate with Siriraj researchers and academic staff to enable Siriraj to operate more efficiently. Both parties will work together in other jointly-developed projects that may arise in the course of the MoU. Siriraj will participate with Huawei for further 5G ecosystem partnership cooperation to promote 5G technology and innovations, in the form of demonstration events and exhibitions. The hospital will also work with Huawei for joint academic sessions, to arrange training classes or technology sharing opportunities, and to study the latest technology topics including, but not limited to, 5G, AI and Cloud. THE LARGER TREND Siriraj Hospital, which is Thailand’s largest government hospital, is the first hospital in Southeast Asia to deploy two NVIDIA DGX A100 systems for medical research and clinical applications, Healthcare IT News reported. In South Korea, KT, the country’s largest telecommunications company and Samsung Medical Center are jointly developing a 5G-powered medical service as an initial step to establishing a 5G smart hospital. The two partners have been applying 5G on site to create better medical services since they signed a MoU in September 2019. ON THE RECORD “It is an honor for Faculty of Medicine Siriraj Hospital to partner with Huawei for this MoU that will raise the level and standards of our services and improve operational efficiency. This marks the initial step to establishing Thailand's first 5G smart state hospital,” said Prof. Dr. Prasit Watanapa, Dean of the Faculty of Medicine Siriraj Hospital, Mahidol University. “The healthcare sector can benefit immensely from smart innovations and infrastructure during this era of digitalization. We would like to accompany Thailand as it develops a strong, connected healthcare ecosystem in order to increase healthcare penetration in rural and remote communities and improve the quality of life of the people,” said Abel Deng, CEO of Huawei Technologies (Thailand).

100 Deals associated with Faculty of Medicine Siriraj Hospital

100 Translational Medicine associated with Faculty of Medicine Siriraj Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 21 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Phase 1 Clinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

CD19 CAR-T (Faculty of Medicine Siriraj Hospital) ( CD19 )	Non-Hodgkin Lymphoma More	Phase 1
VP-001 (PYC Therapeutics) ( CNOT3 x PRPF31 )	Retinitis Pigmentosa 11 More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis